• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The role of HER-2 in Breast Cancer.HER-2在乳腺癌中的作用。
J Surg Sci. 2014 Dec;2(1):4-9.
2
Clinical significance of Mena and Her-2 expression in breast cancer.Mena和Her-2在乳腺癌中的表达的临床意义
Eur J Gynaecol Oncol. 2012;33(5):455-8.
3
HER-2/neu and topoisomerase IIalpha in breast cancer.乳腺癌中的HER-2/neu与拓扑异构酶IIα
Breast Cancer Res Treat. 2003 Apr;78(3):299-311. doi: 10.1023/a:1023077507295.
4
Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.膜联蛋白A2及其下游的白细胞介素-6和肝素结合表皮生长因子作为分泌生物标志物在人表皮生长因子受体2阴性乳腺癌鉴别诊断中的应用
Ann Clin Biochem. 2017 Jul;54(4):463-471. doi: 10.1177/0004563216665867. Epub 2016 Aug 5.
5
The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).HER-2癌蛋白在乳腺癌药物敏感性中的作用（综述）
Oncol Rep. 2002 Jan-Feb;9(1):3-9.
6
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.油酸是橄榄油中的主要单不饱和脂肪酸，它能抑制Her-2/neu（erbB-2）的表达，并协同增强曲妥珠单抗（赫赛汀）对具有Her-2/neu癌基因扩增的乳腺癌细胞的生长抑制作用。
Ann Oncol. 2005 Mar;16(3):359-71. doi: 10.1093/annonc/mdi090. Epub 2005 Jan 10.
7
Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.人表皮生长因子受体2阴性乳腺癌标本中趋化因子受体CXCR4水平升高预示复发。
J Surg Res. 2007 Jul;141(1):53-9. doi: 10.1016/j.jss.2007.03.015.
8
Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage.来自17q11 - 12的扩增Pip4k2beta基因在乳腺癌细胞中的过表达赋予了增殖优势。
Oncogene. 2004 Feb 19;23(7):1354-63. doi: 10.1038/sj.onc.1207251.
9
Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.靶向脂肪酸合酶驱动的脂筏：克服乳腺癌细胞曲妥珠单抗耐药性的新策略。
Med Hypotheses. 2005;64(5):997-1001. doi: 10.1016/j.mehy.2004.09.027.
10
The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.血清HER-2水平及HER-2密码子655多态性对乳腺癌预后的影响。
Neoplasma. 2008;55(2):113-21.

引用本文的文献

1
Newly synthesized chitosan nanoparticles loaded with caffeine/moringa leaf extracts Halt Her2, BRCA1, and BRCA2 expressions.新合成的载有咖啡因/辣木叶提取物的壳聚糖纳米颗粒能抑制 Her2、BRCA1 和 BRCA2 的表达。
Sci Rep. 2024 Aug 5;14(1):18118. doi: 10.1038/s41598-024-67599-1.
2
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study.BP02（曲妥珠单抗生物类似药）与欧盟和美国批准的曲妥珠单抗在健康成年男性志愿者中的药代动力学、安全性、耐受性和免疫原性：一项1期随机双盲研究。
Oncol Ther. 2024 Sep;12(3):477-490. doi: 10.1007/s40487-024-00289-0. Epub 2024 Jul 7.
3
Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor.利用光学纳米传感器快速鉴别患者活检乳腺癌抽吸物中的雌激素受体状态。
bioRxiv. 2024 Apr 1:2024.03.29.587397. doi: 10.1101/2024.03.29.587397.
4
Diagnostic Accuracy of Immunohistochemistry for HER2-Positive Breast Cancer.免疫组织化学检测用于 HER2 阳性乳腺癌的诊断准确性。
Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4321-4327. doi: 10.31557/APJCP.2023.24.12.4321.
5
Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics.靶向HER2阳性乳腺癌细胞的肽及其在肿瘤成像和化疗药物递送中的应用。
Nanomaterials (Basel). 2023 Sep 1;13(17):2476. doi: 10.3390/nano13172476.
6
Evaluation of the Anti-Metastatic Effect of Foeniculum Vulgare on the Protein Expression of HSP 70 & 90 in Balb/c Mice with 4t1 Model of Breast Cancer.评价小茴香对 4t1 乳腺癌模型 Balb/c 小鼠 HSP70 和 HSP90 蛋白表达的抗转移作用。
Asian Pac J Cancer Prev. 2023 Mar 1;24(3):833-840. doi: 10.31557/APJCP.2023.24.3.833.
7
Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor.曲妥珠单抗和PD-1/PD-L1抑制剂作用下HER2阳性乳腺癌集落生长抑制的定量分析
Front Oncol. 2022 Dec 7;12:977664. doi: 10.3389/fonc.2022.977664. eCollection 2022.
8
Feline Oncogenomics: What Do We Know about the Genetics of Cancer in Domestic Cats?猫肿瘤基因组学：我们对家猫癌症遗传学了解多少？
Vet Sci. 2022 Oct 4;9(10):547. doi: 10.3390/vetsci9100547.
9
The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart.分子识别的演变：从抗体到作为人工对应物的分子印迹聚合物（MIPs）
J Funct Biomater. 2022 Jan 28;13(1):12. doi: 10.3390/jfb13010012.
10
Embracing Mechanobiology in Next Generation Organ-On-A-Chip Models of Bone Metastasis.在下一代骨转移器官芯片模型中融入力学生物学
Front Med Technol. 2021 Sep 1;3:722501. doi: 10.3389/fmedt.2021.722501. eCollection 2021.

本文引用的文献

1
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.拉帕替尼联合卡培他滨治疗人表皮生长因子受体 2 阳性晚期乳腺癌的Ⅲ期随机临床试验最终生存分析
Oncologist. 2010;15(9):924-34. doi: 10.1634/theoncologist.2009-0181. Epub 2010 Aug 24.
2
A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer.基于人表皮生长因子受体 2 表达的可手术乳腺癌新辅助化疗方法。
Jpn J Clin Oncol. 2010 Jul;40(7):620-6. doi: 10.1093/jjco/hyq020. Epub 2010 Mar 18.
3
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.高危型原发性乳腺癌中 HER2、TOP2A 与蒽环类药物为基础的术前化疗反应的相关性。
Breast Cancer Res Treat. 2010 Apr;120(2):481-9. doi: 10.1007/s10549-010-0744-z. Epub 2010 Feb 4.
4
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助化疗联合辅助曲妥珠单抗与单纯新辅助化疗治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌患者（NOAH 试验）：一项具有平行人表皮生长因子受体 2 阴性队列的随机对照优效性试验。
Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.
5
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.氟尿嘧啶、表柔比星和环磷酰胺联合多西他赛或长春瑞滨，联合或不联合曲妥珠单抗，作为乳腺癌辅助治疗：芬兰乳腺癌试验（FinHer Trial）的最终结果
J Clin Oncol. 2009 Dec 1;27(34):5685-92. doi: 10.1200/JCO.2008.21.4577. Epub 2009 Nov 2.
6
Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?HER2和TOP2A作为乳腺癌蒽环类辅助化疗的预后或预测生物标志物是否有用？
J Clin Oncol. 2009 Aug 20;27(24):3875-6. doi: 10.1200/JCO.2009.22.8361. Epub 2009 Jul 20.
7
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.与多柔比星联合环磷酰胺相比，多西他赛联合环磷酰胺具有总生存获益：美国肿瘤学研究试验9735的7年随访结果
J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9.
8
Jumping higher: is it still possible? The ALTTO trial challenge.跳得更高：这仍有可能吗？ALTTO试验的挑战。
Expert Rev Anticancer Ther. 2008 Dec;8(12):1883-90. doi: 10.1586/14737140.8.12.1883.
9
HER-2 and topoisomerase II as predictors of response to chemotherapy.HER-2和拓扑异构酶II作为化疗反应的预测指标。
J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716.
10
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.人表皮生长因子受体2（HER2）状态与早期乳腺癌辅助性蒽环类药物的疗效：随机试验的汇总分析
J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. doi: 10.1093/jnci/djm252. Epub 2007 Dec 25.

The role of HER-2 in Breast Cancer.

作者信息

Ishikawa Takashi, Ichikawa Yasushi, Shimizu Daisuke, Sasaki Takeshi, Tanabe Mikiko, Chishima Takashi, Takabe Kazuaki, Endo Itaru

机构信息

Department of Breast Surgery, Tokyo Medical University ( ); Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan ( ); Department of Gastrointestinal Surgery and Department of Clinical Oncology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan ( ), Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan ( ); Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA, USA ( ).

出版信息

J Surg Sci. 2014 Dec;2(1):4-9.

PMID:25679012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4323095/
Abstract
摘要